Ventricular and atrial function assessment with transthoracic echocardiography in patients with rheumatic inflammatory disease

Somayyeh Norouzi1†, Amirmohammad Khalaji2†, Mansoor Namazi3, Somaye Sadat Rezaei4, Amir Hossein Behnoush2 and Maryam Masoumi5*

Abstract

Background: Inflammatory rheumatic diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic sclerosis (SSc), can cause cardiovascular complications in many cases. This study aimed to compare the ventricular and atrial functions of the heart between rheumatic patients and healthy controls using transthoracic echocardiography (TTE).

Results: The study was performed between 64 patients with mentioned rheumatic diseases and 64 age- and sex-matched healthy controls who all underwent detailed history-taking and TTE. Echocardiographic parameters were measured and compared between the two groups. TTE showed significant differences in many echocardiographic parameters. Left ventricular end-diastolic diameter, left ventricular end-systolic diameter, right atrium area, inferior vena cava diameter, and systolic pulmonary artery pressure were significantly higher in patients compared to the controls \( (P < 0.001) \). Left ventricular ejection fraction and right ventricular end-diastolic diameter were not statistically different between the groups \( (P > 0.05) \). Right ventricular septal strain, right ventricular free wall strain, average longitudinal right ventricular strain, tricuspid annular plane systolic excursion, right ventricular systolic myocardial velocity, and right ventricular fractional area change were lower in inflammatory rheumatic patients \( (P < 0.001) \). The subgroup analysis showed the same results’ trend for each disease and its own control group comparison.

Conclusions: Cardiac involvement in rheumatologic diseases, especially SLE, RA, and SSc, should always be taken into consideration as there may be silent changes affecting the overall prognosis of patients. Using TTE helps diagnose and make a treatment plan for cardiovascular complications in rheumatic disease patients.

Keywords: Rheumatic diseases, Systemic lupus erythematosus, Systemic scleroderma, Rheumatoid arthritis, Echocardiography

Background

Rheumatic diseases include but are not limited to systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), vasculitis, systemic sclerosis (SSc), and spondyloarthropathies can cause several comorbidities, among which cardiovascular ones contribute the most to the mortality [1]. These manifestations have been identified and discussed extensively, as some may be the first presentation of the disease [2]. Rheumatic diseases can affect several aspects of the cardiovascular system, from the
pericardium, myocardium, and heart valves to the cardiac conduction system and vasculature [3]. These mainly stem from a combination of traditional cardiovascular risk factors, such as age, gender, obesity, hypertension, diabetes mellitus and smoking, and inflammation caused by rheumatic diseases [4].

Transthoracic echocardiogram (TTE), the most common type of echocardiogram, is a non-invasive, available, and accurate modality to investigate the heart’s structure and diagnose any dysfunction in it. Left ventricular ejection fraction (LVEF), the most common representative of left ventricle (LV) systolic function is mainly measured by TTE. In addition, other parameters represent other cardiac functions and may be used in combination to find a certain pathology [5]. Cardiac manifestations of rheumatic diseases are described in the literature [6], however, few studies evaluated atrial and ventricular functions among patients with these diseases using echocardiography [7]. In this study, we aimed to compare the atrial and ventricular function of the heart between patients with inflammatory rheumatic diseases and age- and sex-matched healthy controls using TTE for the detection of subclinical changes in rheumatic patients.

Methods
Study design and subjects
In this case–control study, 64 patients with confirmed known inflammatory rheumatic diseases and 64 healthy individuals matched to the patients on the basis of age and sex referred to our institute were selected. All the patients selected were known cases of rheumatic inflammatory disease, including SSc, SLE, RA, or mixed connective tissue disease (MCTD) and none of them were in their flare episodes. All the controls were screened for rheumatic inflammatory diseases and were healthy. We excluded individuals with previous cardiac symptoms or known cardiovascular diseases and controls that used possibly confounding medication. Past medical history was taken from patients, including any chronic underlying diseases, smoking status, and drug history. This study was approved by the ethics committee of the Qom University of Medical Sciences (IR.MUQ.REC.1400.225) and informed consent was taken from all participants.

Initial clinical assessment
An expert cardiologist measured the heart rate (HR), systolic blood pressure (SBP), and diastolic blood pressure (DBP) in both the patients and the control group. Height and weight were measured using common clinical devices by a research clinician. Body surface area (BSA) was reported according to the American Society of Echocardiography (ASE) as a commonly used metric for body size modification from weight and height using Boyd’s formula [8].

Echocardiography assessment
TTE was performed according to standardized procedures for the patients and healthy individuals. The cardiologist interpreting echocardiograms was blinded to the group of participants. All procedure techniques and formulas were according to the ASE guidelines [8]. LVEF, LV end-diastolic diameter (LVEDD), LV end-systolic diameter (LVESD), right ventricular end-diastolic diameter (RVEDD), right atrium (RA) area, right ventricular (RV) septal strain, RV free wall strain, average longitudinal RV strain, tricuspid annular plane systolic excursion (TAPSE), RV systolic myocardial velocity, RV fractional area change (RVFAC), inferior vena cava (IVC) diameter, and systolic pulmonary artery pressure (SPAP) were reported by the sonographer. All measurements were also compared in each rheumatic disease group, including SLE, RA, and SSc.

Statistical analysis
Continuous variables are presented as mean ± standard deviation (SD). The Student’s t-test was used to assess the significance of differences between inflammatory rheumatic patients and healthy individuals; and other analyses for continuous variables. The Chi-square test was used for categorical variables to calculate P value. Subgroup analyses were performed based on the rheumatic disease when possible. Statistical significance was considered a two-sided P value of less than 0.05 in analyses. All analyses were performed using the Statistical Package for the Social Sciences (SPSS), version 26 (IBM Corp., Armonk, NY, USA).

Results
Patient population and baseline characteristics
We included 64 patients with inflammatory rheumatic diseases comprised of SLE (n = 30), SSc (n = 21), RA (n = 10), and MCTD (n = 3) in addition to 64 age- and sex-matched healthy individuals. The duration of rheumatic diseases was 36 [12–75] (median [interquartile range]) months. Four patients with hypothyroidism, three with anemia, and two with mild fatty liver were recognized upon history-taking. Smoking was seen only in two patients. Each group consisted of 11 males and 53 females. There was no significant difference between patients and controls in terms of SBP (115.05±6.20 vs. 111.55±18.82; P = 0.160), DBP (73.45±5.26 vs. 73.22±4.52; P = 0.787), and BSA (1.661±0.0572 vs. 1.664±0.0497; P = 0.767). A significant difference between baseline HR was seen between patients and
controls (79.61 ± 6.99 vs. 76.75 ± 6.84; \( P = 0.021 \)). Table 1 summarizes the demographic data of participants.

**Echocardiographic findings**

The complete results of TTE are available in Table 2. There were no significant differences in LVEF and RVEDD between patients and controls (53.91 ± 6.00 vs. 55.16 ± 0.88, \( P = 0.104 \) and 28.66 ± 2.69 vs. 28.05 ± 1.69, \( P = 0.128 \), respectively). However, LVEDD, LVESD, and RA area were significantly higher in patients compared to the controls (\( P < 0.001 \)). Moreover, there were significantly higher IVC diameter and PASP in patients compared to the controls (15.03 ± 3.18 vs. 12.06 ± 2.14, \( P < 0.001 \), and 30.61 ± 8.51 vs. 19.19 ± 1.92, \( P < 0.001 \), respectively). All other measures, including average longitudinal RV strain, TAPSE, RV systolic myocardial velocity, and RV fractional change area were significantly lower in patients compared to the controls (\( P < 0.001 \)).

In rheumatic disease subgroups, the results were almost similar with minor differences. There was no significant difference in the RA area between SSc patients and their controls (12.67 ± 2.35 vs. 11.62 ± 2.29, \( P = 0.152 \)). In RA cases and controls, the RV-free wall strain and IVC diameter lost their significance (\( P = 0.479 \) and \( P = 0.120 \), respectively).

**Discussion**

In this study, we evaluated the atrial and ventricular function of inflammatory rheumatic disease patients and compared them with healthy controls. Almost all parameters in patients with rheumatic disease except LVEF and RVEDD significantly differed from the control group. Subgroup analyses showed cardiac involvement in each SLE, SSc, and RA group.

Rheumatic diseases are responsible for myocardial, pericardial, valvular, electrical, and vascular changes in the cardiovascular system [3]. Increased levels of proinflammatory cytokines [9], atherosclerosis [10], chronic inflammation [11], and underlying autoimmune mechanisms are related to cardiovascular involvement in patients with rheumatic diseases [12]. As cardiovascular manifestations of rheumatic diseases may be silent or mild, early diagnosis and treatment help reduce mortality and morbidity [2]. Our findings implied that even rheumatic disease patients on treatment may have abnormal TTE findings.

SLE is an autoimmune disease that can affect various organs, including the cardiovascular system [13]. It has been shown that cardiovascular events are also higher in SLE patients compared with healthy controls [14]. In our study, LVEF was not significantly different between SLE patients and healthy individuals, which is similar to the study by Huang et al. [15], although, a difference was observed when it came to the 3D echocardiography in this study. While LVEDD and LVESD were higher in SLE patients, RVEDD and RA were the only indifferent parameters between SLE and healthy subjects. Luo et al. assessed echocardiographic findings in SLE patients with different levels of pulmonary hypertension and they found no difference in terms of RVEDD and RV fractional area curve and TAPSE except for the ones with moderate/severe pulmonary hypertension [16]. All in all, cardiac involvement is serious in SLE patients, and even in asymptomatic patients; a non-invasive method such as echocardiography can be helpful for the early detection of abnormalities [17].

Manifestations of SSc as another autoimmune disease are not limited to the skin, in a way that it can affect the whole body, including musculoskeletal, pulmonary, gastrointestinal, renal, endocrine, and cardiovascular systems [18]. Cardiac complications of SSc may manifest as myocardial or pericardial damage, conduction

**Table 1 Baseline characteristics**

|                    | Cases                           | Controls (\( n = 64 \)) | \( p \) value |
|--------------------|---------------------------------|-------------------------|---------------|
|                    | All rheumatic diseases (\( n = 64 \)) | SLE (\( n = 30 \)) | SSc (\( n = 21 \)) | RA (\( n = 10 \)) |
| Sex (\( n \))      |                                 |                         |               |
| Male               | 11                              | 6                       | 2             | 2             | 11            | 1.000          |
| Female             | 53                              | 24                      | 19            | 8             | 53            |               |
| Age                | 38.22 ± 11.09                   | 35.13 ± 9.19            | 41.33 ± 13.79 | 42.10 ± 8.90 | 37.64 ± 9.57 | 0.753          |
| Systolic blood pressure (mmHg) | 115.05 ± 6.20        | 116.17 ± 5.67           | 113.52 ± 7.51 | 114.90 ± 5.45 | 111.55 ± 18.82 | 0.160          |
| Diastolic blood pressure (mmHg) | 73.45 ± 5.26        | 74.33 ± 5.25            | 72.52 ± 5.53  | 72.20 ± 4.73  | 73.22 ± 4.52  | 0.787          |
| Heart rate (pulse/min) | 79.61 ± 6.99        | 80.20 ± 8.77            | 78.52 ± 5.47  | 79.20 ± 4.18  | 76.75 ± 6.84  | 0.021          |
| Body surface area (m²) | 1.661 ± 0.0572       | 1.667 ± 0.0392          | 1.640 ± 0.0780 | 1.681 ± 0.0477 | 1.664 ± 0.0497 | 0.767          |

Data are represented as mean ± standard deviation for continuous variables

SLE systemic lupus erythematosus, SSc systemic sclerosis, RA rheumatoid arthritis
Table 2  Echocardiography results

|                      | All rheumatic diseases | SLE (n = 30) | Systemic sclerosis (n = 21) | Rheumatoid arthritis (n = 10) |
|----------------------|------------------------|--------------|-----------------------------|-------------------------------|
|                      | HC (n = 64) | Cases (n = 64) | P value | HC | SLE | p value | HC | SSc | p value | HC | RA | p value |
| LVEF (%)             | 55.16 ± 0.88 | 53.91 ± 6.00 | 0.104 | 55.17 ± 0.91 | 54.33 ± 2.54 | 0.099 | 55.24 ± 1.09 | 55.00 ± 2.24 | 0.663 | 55.00 ± 0.00 | 54.50 ± 1.58 | 0.331 |
| LVEDD (mm)           | 40.03 ± 3.35 | 47.23 ± 3.82 | <0.001 | 39.57 ± 3.45 | 47.03 ± 4.13 | <0.001 | 39.48 ± 2.66 | 46.95 ± 3.58 | <0.001 | 41.90 ± 3.76 | 48.20 ± 3.05 | 0.001 |
| LVESD (mm)           | 23.27 ± 4.84 | 30.86 ± 4.90 | <0.001 | 23.10 ± 4.55 | 30.37 ± 5.23 | <0.001 | 22.19 ± 4.66 | 29.52 ± 3.43 | <0.001 | 25.30 ± 5.62 | 33.50 ± 3.92 | 0.001 |
| RVEDD (mm)           | 28.05 ± 1.69 | 28.66 ± 2.69 | 0.128 | 27.90 ± 1.71 | 28.37 ± 3.00 | 0.463 | 28.00 ± 1.55 | 28.38 ± 2.08 | 0.505 | 28.30 ± 2.06 | 29.00 ± 1.83 | 0.431 |
| RA area (cm²)        | 11.41 ± 1.90 | 13.07 ± 2.85 | <0.001 | 11.50 ± 1.80 | 13.17 ± 3.42 | 0.022 | 11.62 ± 2.29 | 12.67 ± 2.35 | 0.152 | 11.10 ± 1.45 | 13.05 ± 2.17 | 0.029 |
| RV septal strain (%) | 21.05 ± 2.11 | 16.33 ± 4.00 | <0.001 | 20.83 ± 2.35 | 16.03 ± 4.31 | <0.001 | 20.67 ± 1.93 | 15.90 ± 2.93 | <0.001 | 22.00 ± 1.49 | 17.40 ± 4.95 | 0.017 |
| RV free wall strain (%) | 26.47 ± 2.59 | 23.23 ± 4.14 | <0.001 | 26.73 ± 1.87 | 23.07 ± 4.00 | <0.001 | 26.19 ± 1.89 | 22.57 ± 3.70 | <0.001 | 25.80 ± 4.76 | 24.30 ± 4.52 | 0.479 |
| Average longitudinal RV strain (%) | 24.09 ± 2.08 | 19.31 ± 3.68 | <0.001 | 24.10 ± 1.99 | 19.03 ± 3.52 | <0.001 | 23.48 ± 1.89 | 18.67 ± 3.10 | <0.001 | 24.80 ± 2.25 | 20.70 ± 4.57 | 0.020 |
| TAPSE (mm)           | 25.61 ± 1.53 | 21.70 ± 2.99 | <0.001 | 25.77 ± 1.28 | 21.77 ± 2.49 | <0.001 | 25.62 ± 1.53 | 22.33 ± 2.94 | <0.001 | 25.10 ± 2.28 | 20.90 ± 3.32 | 0.004 |
| RV systolic myocardial velocity (cm/s) | 15.86 ± 1.48 | 12.73 ± 2.30 | <0.001 | 15.97 ± 1.40 | 12.70 ± 2.31 | <0.001 | 16.60 ± 1.34 | 13.05 ± 2.06 | <0.001 | 15.10 ± 2.02 | 12.50 ± 1.51 | 0.004 |
| RV fractional area change (%) | 37.83 ± 3.13 | 29.53 ± 7.18 | <0.001 | 37.67 ± 2.93 | 29.44 ± 7.37 | <0.001 | 37.14 ± 3.18 | 27.42 ± 6.41 | <0.001 | 38.80 ± 3.22 | 32.30 ± 4.42 | 0.001 |
| IVC diameter (mm)    | 12.06 ± 2.14 | 15.03 ± 3.18 | <0.001 | 11.67 ± 2.29 | 15.07 ± 2.91 | <0.001 | 12.48 ± 2.46 | 15.52 ± 3.38 | <0.002 | 12.00 ± 1.33 | 13.30 ± 2.11 | 0.120 |
| SPAP                 | 19.19 ± 192 | 30.61 ± 8.51 | <0.001 | 19.17 ± 1.58 | 30.43 ± 9.84 | <0.001 | 18.90 ± 2.00 | 31.81 ± 7.42 | <0.001 | 20.20 ± 2.62 | 27.80 ± 5.10 | 0.001 |

Data are represented as mean ± standard deviation for continuous variables

HC healthy control, SLE systemic lupus erythematosus, SSc systemic sclerosis, RA rheumatoid arthritis, LVEF left ventricular ejection fraction, LVEDD left ventricular end-diastolic diameter, LVESD left ventricular end-systolic diameter, RVEDD right ventricular end-diastolic diameter, RA right atrium, RV right ventricle, TAPSE tricuspid annular plane systolic excursion, IVC inferior vena cava, SPAP systolic pulmonary artery pressure
system fibrosis, and valvular diseases; however, pulmo-
mary hypertension caused by SSc is also responsible for
cardiovascular involvement [19]. In a study by Huez et al.,
right ventricular diastolic dysfunction was seen among
patients diagnosed with SSc, caused by latent pulmonary hypertension [20]. Following with the mentioned study,
our study showed that the SPAP in the patient group
was approximately 1.7 times that of the control group,
indicating the presence of pulmonary hypertension in a
significant proportion of SSc patients. Therefore, a sim-
ple TTE can have clinical implications in preventing this
serious complication.

RA with a prevalence of about 1%, can have extra-
articular presentations, including cardiovascular ones
[21, 22]. Pericarditis is the most common cardiac mani-
 festation, followed by myocarditis, congestive heart fail-
ure, cardiomyopathy, and pericardial effusion [23]. The
findings of our study suggest left ventricular dysfunction
in RA cases shown by several parameters. This is in line
with the results of a study by Myasoedova et al., which
showed abnormal LV remodeling in RA patients without
heart failure [24].

Although we did our best to make the study flawless,
there were some limitations to our study. First, all the
patients were selected from one center with the same
ethnicity, which may threaten its generalizability. Sec-
ond, despite highly-skilled cardiologists performing the
TTE, this test is operator-related and may be erroneous
in some cases. Finally, echocardiographic assessment
in inflammatory rheumatic diseases has not been done
much in the literature, and further research with more
sample size is highly recommended.

Conclusions
In conclusion, cardiac involvement in rheumatic diseases,
especially SLE, SSc, and RA should always be considered
as there may be silent changes in the heart affecting the
overall prognosis of patients. Echocardiography is a safe
and feasible tool for clinicians to diagnose and prevent
such complications and reduce the total burden of the
diseases.

Abbreviations
SLE: Systemic lupus erythematosus; RA: Rheumatoid arthritis; SSc: Systemic sclerosis; TTE: Transthoracic echocardiography; LV: Left ventricular ejection fraction; LV: Left ventricle; MCTD: Mixed connective tissue disease; HR: Heart rate; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BSA: Body sur-
face area; ASE: American Society of Echocardiography; LVEDD: Left-ventricular end-diastolic diameter; LVEF: Left-ventricular ejection fraction; RV: Right ventricle; TAPSE: Tricuspid annular plane systolic excursion; RVFAC: Right ventricular fractional area change; IVC: Inferior vena cava; SPAP: Systolic pulmonary artery pressure; SD: Standard deviation; SPSS: Statistical package for the social sciences.

Acknowledgements
None.

Author contributions
SN: study conception/manuscript drafting/data collection/critical revision, AK: manuscript drafting/data analysis/revision, MN: manuscript drafting/revision, SSR: manuscript writing/revision, AHB: manuscript writing/revision, MM: study conception/manuscript drafting/data collection/critical revision. All authors have read and approved the manuscript.

Funding:
None.

Availability of data and materials
The datasets generated and/or analyzed during the current study are not
publicly available due they are part of a database, containing further, not yet
published data. However, data used in this study are available from the cor-
responding author on reasonable request.

Declarations

Ethics approval and consent to participate
All the experimental protocol involving humans was in accordance with
guidelines of national/international/institutional or Declaration of Helsinki in
the manuscript. This study was approved by the ethics committee of the Qom
University of Medical Sciences (IRMUQREC.1400.225). As all the patients and
controls were more than 16 years old, written informed consent was taken
from all participants to participate in this study.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interest.

Author details
1 Department of Internal Medicine Science, Qom University of Medical Sciences, Qom, Iran. 2 School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 3 Cardiology Research Department, Qom University of Medical Sciences, Qom, Iran. 4 Faculty of Medicine, Qom University of Medical Sciences, Qom, Iran. 5 Clinical Research and Development Center, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran.

Received: 12 September 2022   Accepted: 20 November 2022

Published online: 25 November 2022

References:
1. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D (2012) Risk of incident cardiovascular events in patients with rheuma-
toid arthritis: a meta-analysis of observational studies. Ann Rheum Dis
71(9):1524–1529
2. Prasad M, Hermann J, Gabriel SE, Weyand CM, Mulvagh S, Mankad R et al (2015) Cardiorheumatology: cardiac involvement in systemic rheumatic
disease. Nat Rev Cardiol 12(3):168–176
3. Kita G, Banks MJ, Bacon PA (2001) Cardiac involvement in rheumatoid disease. Clin Med (Lond) 1(1):18–21
4. Nurmohamed MT, Heslinga M, Kita G (2015) Cardiovascular comorbid-
ity in rheumatic diseases. Nat Rev Rheumatol 11(12):693–704
5. Koui S, Caballero L, Dulgheru R, Voilfit D, De Sousa C, Kcharara G et al (2014) Echocardiographic reference ranges for normal cardiac chamber
size: results from the NORRE study. Eur Heart J - Cardiovasc Imaging
15(6):680–690
6. Ovilia MB, Mostafavi Pour Marshadi SMY, Naderi N (2012) Cardiac
manifestations of rheumatological conditions: a narrative review. ISRN
Rheumatol 2012:463620
7. Makavos G, Varoudi M, Papangelopoulou K, Kapniera E, Plotas P, Ikonoi-
midis I et al (2020) Echocardiography in autoimmune rheumatic diseases
for diagnosis and prognosis of cardiovascular complications. Medicina
(Kaunas) 56(9):445
8. Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finnstuen JA, Foster MC
et al (2019) Guidelines for performing a comprehensive transthoracic

echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr 32(1):1–64
9. Guilherme L, Cury P, Demarchi LM, Coelho V, Abel L, Lopez AP et al (2004) Rheumatic heart disease: proinflammatory cytokines play a role in the progression and maintenance of valvular lesions. Am J Pathol 165(5):1583–1591
10. Ruscitti P, Cipriani P, Liakouli V, Iacono D, Pantano I, Margiotta DPE et al (2019) Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. Arthritis Res Ther 21(1):204
11. Mason JC, Libby P (2015) Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J 36(8):482–489
12. Klingenberg R (2017) The heart in rheumatic, autoimmune and inflammatory diseases. Eur Heart J 38(40):2985
13. Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthr Rheum: Off J Am Coll Rheumatol 25(11):1271–1277
14. Manz S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L et al (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145(5):408–415
15. Huang BT, Yao HM, Huang H (2014) Left ventricular remodeling and dysfunction in systemic lupus erythematosus: a three-dimensional speckle tracking study. Echocardiography 31(9):1085–1094
16. Luo R, Cui H, Huang D, Sun L, Song S, Sun M et al (2018) Early assessment of right ventricular function in systemic lupus erythematosus patients using strain and strain rate imaging. Arq Bras Cardiol 111(1):75–81
17. Mohammed AG, Alghamdi AA, MA AL, Al-Homood IA. Echocardiographic findings in asymptomatic systemic lupus erythematosus patients. Clin Rheumatol 2017;36(3):563–8.
18. Adigun R, Goyal A, Hariz A (2022) Systemic sclerosis. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC
19. Lambova S (2014) Cardiac manifestations in systemic sclerosis. World J Cardiol 6(9):993–1005
20. Huez S, Roufosse F, Vachiéry JL, Pavelescu A, Derumeaux G, Wautelet JC et al (2007) Isolated right ventricular dysfunction in systemic sclerosis: Latent pulmonary hypertension? Eur Respir J 30(5):928–936
21. Drossaers-Bakker KW, Zwinderman AH, Vliegenthart RF, Van Zeben D, Vos K, Breedveld FC et al (2002) Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthr Rheum 47(4):383–390
22. Braunwald E (2001) Textbook of heart disease. Harcourt, Brace
23. Rawla P (2019) Cardiac and vascular complications in rheumatoid arthritis. Reumatologia 57(1):27–36
24. Myasoedova E, Davis JM 3rd, Crowson CS, Roger VL, Karon BL, Borgeson DD et al (2013) Brief report: rheumatoid arthritis is associated with left ventricular concentric remodeling: results of a population-based cross-sectional study. Arthr Rheum 65(7):1713–1718

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ➤ springeropen.com